abstract |
The present invention relates to Norrin or a functional fragment thereof in the treatment or prevention of diseases associated with an increased TGF-beta activity. In particular, the use of said Norrin or functional fragment thereof to treat fibrotic diseases/disorders or proliferative disorders, like cancers, is part of this invention. |